Discover and read the best of Twitter Threads about #PolyICLC
Most recents (5)
$NWBO #DCVaxL
The #PolyICLC adjuvant has already been approved for adjuvant use in other cancers. Under new FDA rules, real world data and validation of the results already seen may make it very easy not only to expand the label and access to #Hiltonol, but also ease insurance / Medicare if
If #DCVaxL is approved. It should be straightforward to add #PolyICLC $NWBO.
See, “Poly ICLC (Hiltonol®): an immune adjuvant targeting the Toll-like receptor 3 (TLR3) pathway; approved for subsets of patients with squamous cell carcinoma”
cancerresearch.org/treatment-type…
See, “Poly ICLC (Hiltonol®): an immune adjuvant targeting the Toll-like receptor 3 (TLR3) pathway; approved for subsets of patients with squamous cell carcinoma”
cancerresearch.org/treatment-type…
A lot of people are starting to notice IMHO. $NWBO #DCVaxL
Phase 3 results: $NWBO #DCvaxL
Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination w/Extension of Survival Among Patients w/[BOTH] #NewlyDiagnosed & #Recurrent #Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial #CancerVaccine
jamanetwork.com/journals/jamao…
Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination w/Extension of Survival Among Patients w/[BOTH] #NewlyDiagnosed & #Recurrent #Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial #CancerVaccine
jamanetwork.com/journals/jamao…
Mind blowing interim, unpublished data #DCVaxL data from UCLA #DrLindaLiau presentation for use with adjuvant #PolyICLC #TLR3Agonist #Hiltonol #glioblastoma #cancervaccine
Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy from 2011, #DCVaxL with #PolyICLC #Glioblastoma #GBM
aacrjournals.org/clincancerres/…
aacrjournals.org/clincancerres/…
#DCVaxL & #PolyICLC #TLR3Inhibitor as adjuvant, have been an impressive combination since 2011:
Results: DC vaccinations are safe and not associated with any dose-limiting toxicity.
Results: DC vaccinations are safe and not associated with any dose-limiting toxicity.
The median overall survival from the time of initial surgical diagnosis of glioblastoma was 31.4 months, with a 1-, 2-, and 3-year survival rate of 91%, 55%, and 47%, respectively.
Exploring Adjuvants with #DCVaxL: POLY ICLC TLR 3 Agonist adjuvant discussion, #DrLindaLiau, early trial P 1. Using adjuvants w/ #DCVaxL $NWBO #Murcidencel #DCVax
Survival Data w/Adjuvants, small early trial:
Survival Data w/Adjuvants, small early trial:
Fuller Discussion re early trial with #DCVaxL + adjuvants, including Poly ICLC:
Re single agent checkpoint inhibitors, without DCVaxL, in Glioblastoma:
Dendritic Cell Vaccine for Patients With Brain Tumors - Full Text View - ClinicalTrials.gov
#AdjuvantStimulus #PolyICLC
Ongoing #DCVaxL trial with Adjuvant stimulus, will likely further improve outcomes with #DCVaxL $NWBO clinicaltrials.gov/ct2/show/NCT01…
#AdjuvantStimulus #PolyICLC
Ongoing #DCVaxL trial with Adjuvant stimulus, will likely further improve outcomes with #DCVaxL $NWBO clinicaltrials.gov/ct2/show/NCT01…
